← Back to Clinical Trials
Recruiting NCT06440148

NCT06440148 Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06440148
Status Recruiting
Phase
Sponsor Medical University of Lublin
Condition Mastocytosis
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2019-09-01
Primary Completion 2024-05-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
All Conditions
Interventions
SCLEROSTIN

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2019-09-01 with a primary completion date of 2024-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues. Bones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.

Eligibility Criteria

Inclusion Criteria: * Age \> 18 years * Mastocytosis defined according to WHO criteria * Known KIT mutation status Exclusion Criteria: * History of organ transplant * Inability to give informed consent * Pregnancy, Breastfeeding * Vulnerable Patient, defined as: patient with another uncontrolled severe disease; patient under juridical protection

Contact & Investigator

Central Contact

Aneta Szudy-Szczyrek, MD., PhD.

✉ aneta.szudy-szczyrek@umlub.pl

📞 +48815345468

Principal Investigator

Aneta A Szudy-Szczyrek, MD., PhD.

PRINCIPAL INVESTIGATOR

Medical University of Lublin

Frequently Asked Questions

Who can join the NCT06440148 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Mastocytosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06440148 currently recruiting?

Yes, NCT06440148 is actively recruiting participants. Contact the research team at aneta.szudy-szczyrek@umlub.pl for enrollment information.

Where is the NCT06440148 trial being conducted?

This trial is being conducted at Lublin, Poland.

Who is sponsoring the NCT06440148 clinical trial?

NCT06440148 is sponsored by Medical University of Lublin. The principal investigator is Aneta A Szudy-Szczyrek, MD., PhD. at Medical University of Lublin. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology